Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma.
Gallina FT, Tajè R, Letizia Cecere F, Forcella D, Landi L, Minuti G, Fusco F, Buglioni S, Visca P, Melis E, Sperduti I, Ciliberto G, Cappuzzo F, Facciolo F. Gallina FT, et al. Among authors: ciliberto g. Lung Cancer. 2023 Jun;180:107215. doi: 10.1016/j.lungcan.2023.107215. Epub 2023 Apr 25. Lung Cancer. 2023. PMID: 37126920
A prognostic score from a multicentric retrospective analysis of patients affected by sarcoma with metachronous lung metastases undergoing metastasectomy.
Gallina FT, Melis E, Bertolaccini L, Spaggiari L, Rocca M, Donati DM, Chiappetta M, Margaritora S, Bertoglio P, Solli P, Mammana M, Rea F, Onesti EC, Ferraresi V, Sperduti I, Ciliberto G, Facciolo F. Gallina FT, et al. Among authors: ciliberto g. J Surg Oncol. 2023 May;127(6):1035-1042. doi: 10.1002/jso.27219. Epub 2023 Feb 20. J Surg Oncol. 2023. PMID: 36807911 Clinical Trial.
Development of a somatic variant registry in a National Cancer Center: towards Molecular Real World Data preparedness.
Betti M, Maria Salzano C, Massacci A, D'Antonio M, Grassucci I, Marcozzi B, Canfora M, Melucci E, Buglioni S, Casini B, Gallo E, Pescarmona E, Ciliberto G, Pallocca M. Betti M, et al. Among authors: ciliberto g. J Biomed Inform. 2023 Jun;142:104394. doi: 10.1016/j.jbi.2023.104394. Epub 2023 May 18. J Biomed Inform. 2023. PMID: 37209976 Free article.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Di Lisa FS, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, Borella F, Foglietta J, Cariello A, Ferro A, Picardo E, Mitidieri M, Sini V, Stani S, Tonini G, Santini D, La Verde N, Gambaro AR, Grassadonia A, Tinari N, Garrone O, Sarobba G, Livi L, Meattini I, D'Auria G, Vergati M, Gamucci T, Pistelli M, Berardi R, Risi E, Giotta F, Lorusso V, Rinaldi L, Artale S, Cazzaniga ME, Zustovich F, Cappuzzo F, Landi L, Torrisi R, Scagnoli S, Botticelli A, Michelotti A, Fratini B, Saltarelli R, Paris I, Muratore M, Cassano A, Gianni L, Gaspari V, Veltri EM, Zoratto F, Fiorio E, Fabbri MA, Mazzotta M, Ruggeri EM, Pedersini R, Valerio MR, Filomeno L, Minelli M, Scavina P, Raffaele M, Astone A, De Vita R, Pozzi M, Riccardi F, Greco F, Moscetti L, Giordano M, Maugeri-Saccà M, Zennaro A, Botti C, Pelle F, Cappelli S, Cavicchi F, Vizza E, Sanguineti G, Tomao F, Cortesi E, Marchetti P, Tomao S, Speranza I, Sperduti I, Ciliberto G, Vici P. Di Lisa FS, et al. Among authors: ciliberto g. Front Oncol. 2023 May 16;13:1152123. doi: 10.3389/fonc.2023.1152123. eCollection 2023. Front Oncol. 2023. PMID: 37260975 Free PMC article.
Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report.
Orciuolo C, Cappuzzo F, Landi L, Resuli B, Carpano S, Vidiri A, Buglioni S, Mandoj C, Ciliberto G, Minuti G. Orciuolo C, et al. Among authors: ciliberto g. JTO Clin Res Rep. 2023 Jun 30;4(8):100545. doi: 10.1016/j.jtocrr.2023.100545. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37533438 Free PMC article.
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P, Valenti F, Allegretti M, Pallocca M, De Nicola F, Ciuffreda L, Fanciulli M, Scalera S, Buglioni S, Melucci E, Casini B, Carosi M, Pescarmona E, Giordani E, Sperati F, Jannitti N, Betti M, Maugeri-Saccà M, Cecere FL, Villani V, Pace A, Appetecchia M, Vici P, Savarese A, Krasniqi E, Ferraresi V, Russillo M, Fabi A, Landi L, Minuti G, Cappuzzo F, Zeuli M, Ciliberto G. Giacomini P, et al. Among authors: ciliberto g. J Transl Med. 2023 Oct 16;21(1):725. doi: 10.1186/s12967-023-04595-5. J Transl Med. 2023. PMID: 37845764 Free PMC article.
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Marinelli D, Gallina FT, Pannunzio S, Di Civita MA, Torchia A, Giusti R, Gelibter AJ, Roberto M, Verrico M, Melis E, Tajè R, Cecere FL, Landi L, Nisticò P, Porciello N, Occhipinti M, Brambilla M, Forde PM, Liu SV, Botticelli A, Novello S, Ciliberto G, Cortesi E, Facciolo F, Cappuzzo F, Santini D. Marinelli D, et al. Among authors: ciliberto g. Crit Rev Oncol Hematol. 2023 Dec;192:104190. doi: 10.1016/j.critrevonc.2023.104190. Epub 2023 Oct 21. Crit Rev Oncol Hematol. 2023. PMID: 37871779 Free article.
HER2 mutation as an emerging target in advanced breast cancer.
Bon G, Di Lisa FS, Filomeno L, Arcuri T, Krasniqi E, Pizzuti L, Barba M, Messina B, Schiavoni G, Sanguineti G, Botti C, Cappelli S, Pelle F, Cavicchi F, Puccica I, Costantini M, Perracchio L, Maugeri-Saccà M, Ciliberto G, Vici P. Bon G, et al. Among authors: ciliberto g. Cancer Sci. 2024 May 7. doi: 10.1111/cas.16148. Online ahead of print. Cancer Sci. 2024. PMID: 38715247 Free article. Review.
524 results